Auf unserer Website kommen verschiedene Cookies zum Einsatz: Technisch notwendige Cookies verwenden wir zu dem Zweck, Funktionen wie das Login oder einen Warenkorb zu ermöglichen. Optionale Cookies verwenden wir zu Marketing- und Optimierungszwecken, insbesondere um für Sie relevante und interessante Anzeigen bei den Plattformen von Meta (Facebook, Instagram) zu schalten. Optionale Cookies können Sie ablehnen. Mehr Informationen zur Datenerhebung und -verarbeitung finden Sie in unserer Datenschutzerklärung.
Nicholas M. Dello Russo, DMD, MScD, is an instructor in periodontics at Harvard University School of Dental Medicine and an attending periodontist in the Department of Oral & Maxillofacial Surgery at Massachusetts General Hospital. He is a diplomate of the American Board of Periodontology and a member of Omicron Kappa Upsilon and the International College of Dentists.
Veranstaltungen
The 14th International Symposium on Periodontics and Restorative Dentistry (ISPRD)
9. Juni 2022 — 12. Juni 2022Boston Marriott Copley Place, Boston, MA, Vereinigte Staaten von Amerika
Referenten: Tara Aghaloo, Edward P. Allen, Evanthia Anadioti, Wael Att, Vinay Bhide, Markus Blatz, Scotty Bolding, Lorenzo Breschi, Jeff Brucia, Daniel Buser, Luigi Canullo, Daniele Cardaropoli, Stephen J. Chu, Donald Clem, Christian Coachman, Lyndon F. Cooper, Daniel Cullum, Lee Culp, José Carlos Martins da Rosa, Sergio De Paoli, Marco Degidi, Nicholas Dello Russo, Serge Dibart, Joseph P. Fiorellini, Mauro Fradeani, Stuart J. Froum, David Garber, Maria L. Geisinger, William Giannobile, Luca Gobbato, Ueli Grunder, Galip Gürel, Chad Gwaltney, Christoph Hämmerle, Robert A. Horowitz, Marc Hürzeler, David Kim, Gregg Kinzer, Christopher Köttgen, Ina Köttgen, Purnima S. Kumar, Burton Langer, Lydia Legg, Pascal Magne, Kenneth A. Malament, Jay Malmquist, George Mandelaris, Pamela K. McClain, Michael K. McGuire, Mauro Merli, Konrad H. Meyenberg, Craig M. Misch, Julie A. Mitchell, Marc L. Nevins, Myron Nevins, Michael G. Newman, Miguel A. Ortiz, Jacinthe M. Paquette, Stefano Parma-Benfenati, Michael A. Pikos, Giulio Rasperini, Pamela S. Ray, Christopher R. Richardson, Isabella Rocchietta, Marisa Roncati, Marco Ronda, Paul S. Rosen, Maria Emanuel Ryan, Irena Sailer, Maurice Salama, David M. Sarver, Takeshi Sasaki, Todd Scheyer, Massimo Simion, Michael Sonick, Sergio Spinato, Dennis P. Tarnow, Lorenzo Tavelli, Douglas A. Terry, Tiziano Testori, Carlo Tinti, Istvan Urban, Hom-Lay Wang, Robert Winter, Giovanni Zucchelli
Quintessence Publishing Co., Inc. USA
Zeitschriftenbeiträge dieses Autors
The International Journal of Oral & Maxillofacial Implants, 1/2007
PubMed-ID: 17340909Seiten: 146-153, Sprache: EnglischDello Russo, Nicholas M. / Jeffcoat, Marjorie K. / Marx, Robert E. / Fugazzotto, Paul A.
The development of osteonecrotic lesions of the jaws has been described as being associated with the use of bisphosphonates. Although most clinical reports described the association between necrotic lesions and the use of this group of medications for the management of osseous lesions associated with malignancies such as multiple myeloma, metastatic breast cancer, or prostate cancer, there are reports of osteonecrosis in the jaws of patients who are using oral bisphosphonates to treat osteoporosis.
Given the number of patients taking this medication for the management of osteoporosis, it is obvious that the risks and benefits of the medication need to be clearly defined. Could you comment on the risks of oral bisphosphonate use toward the development of osteonecrotic lesions of the jaws? In addition, could you postulate on studies that may better define this risk?